The approval enables CREATE to start enrolling Australian patients with lupus, systemic sclerosis, and inflammatory myopathies in a first-in-human study of its in vivo CD19-targeted CAR-T therapy, designed to deplete harmful B...
The partnership will move Sonoma Biotherapeutics’ Phase 1 autologous CAR-Treg therapy for treatment-resistant rheumatoid arthritis onto Cellares’ automated manufacturing and quality control systems to improve scalability, consistency, and readiness for later-stage development.
Sad day for the industry, here's a summary of the CEO/Executive Chairman's readouts of the trials.
The Australian biotech company is hoping to tackle aGvHD in Europe, which appears to have twice as many cases as the USA.
Syntax is bringing its Cellgorithm cell-therapy discovery platform to the table, while Mayo Clinic will provide expertise in pancreatic biology and functional testing for preclinical diabetes.
Building on work at the University of Wisconsin-Madison, the Australian biotech company expects to release data from its Phase 3 iPSC-derived MSC KOA & Phase 2 Graft-vs-Host-Disease trials in the coming months.
The company is expanding its preclinical work on acute respiratory syndrome to investigate whether its fibroblasts may help with deadly lung inflammation, vascular leakage, and tissue damage.
The partnership hopes to speed up the scalable development of SC451 for type 1 diabetes by standardizing treatment protocols, improving clinical delivery and post-care, and preparing the therapy for broader use across...
Following their successful Phase 1, they've received clearance to begin Phase 2, where they'll assess whether it can reduce transfusion needs by calming the immune attack on bone marrow.
Cellares said its automated Cell Shuttle platform successfully produced GMP-compliant rese-cel doses for Cabaletta Bio’s RESET trial, marking an early proof point that automation can help lower costs and scale autologous CAR...
